LC KILLS MORE PEOPLE THAN BREAST,
PROSTATE, COLON, LIVER, MELANOMA,
AND KIDNEY CANCERS COMBINED.

 

China Medical Systems gets SFDA approval for Phase II trial for cancer treatment

lung3.jpgChina Medical System Holdings Ltd. said it has received approval from the Chinese State Food and Drug Administration (SFDA) to begin the Phase II clinical trial for CMS024-02 (Tyroservatide), a drug for the treatment of non-small cell lung cancer.

 

Trackback

 

One Response to “China Medical Systems gets SFDA approval for Phase II trial for cancer treatment”

Leave a Reply